Cardioprotective effect of tofisopam against isoprenaline-induced myocardial infarction in rats via modulation of NLRP3\IL-1β\caspase-1 pathway

Alyaa Abdelfattah Abdelmonaem,Asmaa Mohamed Abdel-Aziz,Yasmine F. Ibrahim,Walaa Yehia Abdelzaher,Nada Amgad Mohammed,Heba Marey,Asmaa S. Taghian,Amr Setouhi,Ashraf Radi,Sara M. Ahmed
DOI: https://doi.org/10.1080/08923973.2024.2421528
IF: 3.712
2024-11-07
Immunopharmacology and Immunotoxicology
Abstract:Purpose Cardiovascular diseases (CVDs) are a leading cause of morbidity and mortality worldwide. Ischemic heart diseases, particularly acute myocardial infarction (MI), represent the most common cause of death. MI is influenced by multiple factors, including the release of inflammatory mediators. A significant percentage of individuals with CVD experience psychological effects, such as anxiety and depression, which are linked to an increased risk of coronary heart disease. Certain anti-anxiety medications have demonstrated immunomodulatory and anti-inflammatory effects. Tofisopam, a 2,3-benzodiazepine with anxiolytic properties, has been shown to exert in vitro anti-inflammatory and immunomodulatory effects. The present study investigates the potential of tofisopam as a protective adjuvant against isoprenaline-induced MI in rats and explores the possible underlying mechanisms.
pharmacology & pharmacy,immunology,toxicology
What problem does this paper attempt to address?